AUPH
Aurinia Pharmaceuticals Inc.15.85
+0.16+1.02%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.09BP/E (TTM)
28.30Basic EPS (TTM)
0.56Dividend Yield
0%Recent Filings
10-Q
8-K
10-Q
Q2 FY2025 results
Aurinia Pharmaceuticals posted solid Q2 FY2025 results, with total revenue climbing 22% year-over-year to $70.0 million on $66.6 million in net product sales, up 21% from stronger LUPKYNIS uptake in lupus nephritis markets. Gross margin expanded to 90% from 84%, while operating income swung to $20.1 million from a $1.5 million loss, fueled by 42% lower SG&A after 2024 restructurings that trimmed headcount. Diluted EPS hit $0.16 on 137.5 million shares, consistent with net income of $21.5 million. Cash from operations reached $45.5 million year-to-date, offset by $90.8 million in share repurchases; liquidity stood at $315.1 million, with $75.4 million in Monoplant finance lease debt through 2030. Patent challenges from generic filers loom as a key risk.
8-K
Aurinia boosts revenue, repurchases
Aurinia Pharmaceuticals reported Q2 2025 revenue of $70.0 million, up 22% year-over-year, driven by $66.6 million in LUPKYNIS net product sales amid new ACR guidelines boosting first-line use. The company swung to net income of $21.5 million from a slim $0.7 million profit last year, while boosting its share repurchase plan by $150 million after buying back $90.8 million in shares. Cash stood at $315.1 million. Aurinia raised 2025 revenue guidance to $260-270 million. Strong sales fuel returns to shareholders.
8-K
Positive Phase 1 for AUR200
Aurinia Pharmaceuticals announced positive Phase 1 results for aritinercept (AUR200), a dual BAFF/APRIL inhibitor, on June 30, 2025. Single doses up to 300 mg were well tolerated, with no serious adverse events, and drove robust immunoglobulin reductions—up to 48% in IgA, 55% in IgM, and 20% in IgG by Day 28—supporting once-monthly dosing. The company plans clinical studies in at least two autoimmune diseases in the second half of 2025. Yet development risks loom large.
IPO
Employees
Sector
Industry
AEON
AEON Biopharma, Inc.
1.03+0.17
ALMS
Alumis Inc.
11.40+0.09
AURA
Aura Biosciences, Inc.
6.18-0.15
AURX
Nuo Therapeutics, Inc.
2.00-0.15
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
LBRX
LB Pharmaceuticals Inc
19.82-0.04
LGND
Ligand Pharmaceuticals Incorpor
192.63-0.25
NKTR
Nektar Therapeutics
49.16-4.14
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
TBPH
Theravance Biopharma, Inc.
17.53-0.24